Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies.

Trial Profile

Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies.

Suspended
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2012

At a glance

  • Drugs FP 1039 (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 16 Jun 2012 Planned number of patients changed from 72 to 54 and official title amended as reported by ClinicalTrials.gov.
    • 16 Jun 2012 Investigational drug (Pemetrexed) has been removed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top